current mergers in AI drug discovery firms

Recursion and Exscientia merge with the goal of creating a leading AI-driven drug discovery company with a robust clinical pipeline.

We analyze funding and acquisitions data, clinical progress, and partnership strategies to help pharma companies and investors navigate the maturing AI landscape in drug discovery.

We recently compiled a list of the 35 Trending AI Stocks on Latest News and Analyst Ratings. In this article, we are going to take a look at where Exscientia plc (NASDAQ:EXAI) stan...

We explored ten years of deal-making to assess the impact that AI is having on deals, how it will shape future M&A activity, and why pharma companies need to adapt their approach t...

Application of AI/ML technology and a burst of M&A activity look to be shaping the future of the pharma industry.

The global AI in Drug Discovery Market is projected to reach USD 13 2 billion by 2035 growing at a robust CAGR of 18 4 from 2025 to 2035 This strong growth is driven by the increas...

The global artificial intelligence in drug discovery market was estimated at USD 3.6 billion in 2024. The market is expected to grow from USD 4.6 billion in 2025 to USD 49.5 billio...

Seeking more efficient drug development, pharmaceutical giants and startups are encouraging AI fluency and in some cases offering training for it.

Discover how tech-first companies, like Recursion, Exscientia, BenevolentAI, Insilico Medicine, BPGbio, and Moderna, are leveraging AI drug discovery platforms to revolutionize the...

40% of Global AI Companies Focus on Early Drug Development while AI-Powered Startups Reshape the Future of Drug DiscoveryNew industry report from Deep Pharma Intelligence has redef...


Related Content From The Pandipedia